Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Odevo in connection with the acquisition of OBOS’ 40% minority stake in SBC and OBOS subsequent investment in Odevo
Mandate

Vinge advises Odevo in connection with the acquisition of OBOS’ 40% minority stake in SBC and OBOS subsequent investment in Odevo

April 13, 2022 M&A

Vinge advises Odevo in connection with the acquisition of OBOS minority stake of approx. 40 percent in SBC Intressenter HoldCo AB ("SBC") and OBOS’ subsequent investment in Odevo.

OBOS has been a minority investor in SBC since 2019. Through the divestment of its shares in SBC to Odevo, SBC becomes wholly owned by Odevo. Odevo was launched in February and is a new international player that challenges the traditional industry for property and housing management. The foundation for the group was created in 2019 through the formation of Nabo and the acquisition of SBC, and since then the group has grown into a leading international player. The companies within Odevo offer services to residents and property owners supported by Odevo’s own developed platform. The Odevo Group consists of a total of approximately 1,300 employees and has a turnover of just over SEK 1.5 billion.

Vinge’s team consisted of among others Jonas Bergstöm, Joacim Rydergård and Clara Sohlberg.

 

Related

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

 Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.
May 30, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (“SBB”) in connection with SBB establishing a new joint venture with Castlelake, LP (“Castlelake”).
May 28, 2024

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

 On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.
May 28, 2024